

24 Apr 2022 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: will biotech overcome its slump?; Sanofi on the future of vaccines; J&J's M&A ambitions; interview with a Korean immuno-oncology challenger; and a setback for the IL-2 approach in oncology.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 22 April 2022, including: will biotech overcome its slump; [Sanofi](#) on the future of vaccines; [Johnson & Johnson's](#) M&A ambitions; interview with a Korean immuno-oncology challenger; and a setback for the IL-2 approach in oncology.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Is The Downturn A 'Darwinian Moment' For Biotech? The View From The Frontline](#)" - Scrip, 21 Apr, 2022.)

(Also see "[Sanofi's Triomphe On Vaccine Plants Of The Future, Regulatory Speed](#)" - Scrip, 21 Apr, 2022.)

(Also see "[J&J Continues Signaling Aggressive M&A Approach To Drive Growth](#)" - Scrip, 19 Apr, 2022.)

(Also see "[\*Too Crowded? ImmuneOncia Looks To Niches To Challenge PD-L1 Space\*](#)" - Scrip, 20 Apr, 2022.)

(Also see "[\*Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames\*](#)" - Scrip, 15 Apr, 2022.)

[Click here to explore this interactive content online](#) ✨